Following a recent slew of regulations, pharma companies are increasingly struggling to roll out their products, falling at the commercialisation hurdle. US and EU policies have created a perfect storm for the industry, raising costs and reducing successful launches of new drugs. While many firms are turning to AI for research support, I predict that the technology's greatest value will lie in this area, and in fixing this challenge. By identifying the patient subgroups who would benefit the… [...]
The horrible winter of 2026 is behind us in New England; now we’ve moved on to the season where there’s a threat of rain basically every day. Given that, the updated Storm Radar app from The Weath [...]
Eli Lilly's digital chief admits that, so far, AI is paying off in pharma everywhere except where the industry hyped it most: drug discovery.<br /> The article AI is saving pharma billions [...]
There’s an understandable and undeniable pall hanging over The Last of Us after last week’s shocker. And it’s the calm before the storm that’ll make up the rest of the season: Ellie and Dina†[...]
Anthropic is launching its own drug development program for neglected diseases that the pharmaceutical industry considers unprofitable. Novartis CEO Vas Narasimhan thinks AI could cut development time [...]
Visa's open-source security harness now finds the vulnerability, writes the fix, and turns an adversarial panel on its own patch before any human reviews it. The whole loop ships on by default. A [...]
Big Pharma is pushing to bring back a tax break that could have saved them at least $15.4 billion in 2023 alone, according to a new analysis by Americans for Tax Fairness (ATF) and Lower Drug Prices N [...]